Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
Annual revenue climbed 40% to ₹633.3 crore as the board approved a five-fold expansion of authorised capital to support the bonus issue.
— 1 earlier story on Fredun Pharmaceuticals Ltd. →What's new
- FY26 net profit hit ₹33.2 crore, a 60% increase over the prior year.
- Revenue rose 40% to ₹633.3 crore for the year ended March 2026.
- Board approved a 2:1 bonus issue and a final dividend of 70 paise per share.
Why this matters
The combination of strong earnings growth and a significant bonus issue signals management's confidence in the company's cash position. While the auditor flagged a procedural delay in transferring unclaimed dividends, the core financial performance remains the primary takeaway for shareholders.
What we're watching
- Shareholder approval for the increase in authorised share capital to ₹50 crore.
- The record date for the bonus share distribution.
- Resolution of the auditor's note regarding the Investor Education and Protection Fund.
The full read
Fredun Pharmaceuticals delivered a strong fiscal year, with revenue climbing 40% to ₹633.3 crore and net profit surging 60% to ₹33.2 crore. To mark the performance, the board declared a 2:1 bonus issue and a final dividend of 70 paise per share. The company is also moving to expand its authorised share capital five-fold, from ₹10 crore to ₹50 crore, to facilitate the bonus and provide headroom for future growth. While the auditor issued an unmodified opinion, they flagged a technical lapse regarding the transfer of unclaimed dividends to the Investor Education and Protection Fund. For a micro-cap, the scale of these corporate actions is unusual. The next test for the company is securing shareholder approval for the capital expansion and executing the bonus distribution without further regulatory friction.
Questions answered
- What are the key financial results for FY26?
- Fredun Pharmaceuticals reported revenue of ₹633.3 crore, up 40%, and a net profit of ₹33.2 crore, up 60%.
- What is the bonus share structure?
- The board approved a 2:1 bonus issue, meaning shareholders will receive two new shares for every one share held.
- Why is the company increasing its authorised share capital?
- The company plans to raise its authorised capital from ₹10 crore to ₹50 crore to accommodate the new bonus shares and future capital requirements.
- Did the auditor raise any concerns?
- The audit opinion is unmodified, though the auditor noted a delay in transferring unclaimed dividends to the Investor Education and Protection Fund.
Story so far
All notes on FREDUN →- 25 May 2026 · 10:07 PM IST Fredun Pharmaceuticals posts 60% profit jump and declares 2:1 bonus
- today Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus